Search

View past issues
Record

Comments,
story ideas

Click here to
e-mail the Record

Washington University in St. Louis

Nov. 8, 2002 Vol. 27, No. 11
Front Page
Medical news
Calendar
Notables
Campus Watch
Sports
Record Staff
Employment

Kathy Atnip,
has a penchant for staying ahead of the game


Picturing
Our Past



To current issue



Image matters

Molecular imaging may diagnose disease before symptoms appear

By Darrell E. Ward

School of Medicine researchers are developing methods to track molecular events in the body to diagnose disease long before symptoms appear and to predict the effectiveness of drug therapies.

The research is under way at the medical school’s Molecular Imaging Center at the Mallinckrodt Institute of Radiology. The center is funded by a five-year, $9.4 million grant from the National Cancer Institute.

Third-year graduate student Seth Gammon (left) and David R. Piwnica-Worms, M.D., Ph.D., professor of radiology and of molecular biology and pharmacology, discuss a preparation of molecular imaging probes.
Photo by Bob Boston
Third-year graduate student Seth Gammon (left) and David R. Piwnica-Worms, M.D., Ph.D., professor of radiology and of molecular biology and pharmacology, discuss a preparation of molecular imaging probes.
"Molecular imaging combines the latest in imaging technology with the power of molecular biology," said David Piwnica-Worms, M.D., Ph.D., professor of radiology and of molecular biology and pharmacology and director of the new center.

"We believe that molecular imaging will one day enable us to diagnose specific molecular events of cancer, neurologic disease or inflammation earlier in the course of disease, and that this will help doctors identify the most effective therapy for individual patients."

Piwnica-Worms described molecular imaging and research being done at the center during the 40th Annual New Horizons in Science Briefing, sponsored by the Council for the Advancement of Science Writing, hosted Oct. 27-30 by the University.

Investigators at the center are using molecular imaging to study protein-protein interactions, immune cells attacking a tumor and the course of a viral infection and its response to antiviral therapy.

Other researchers are developing a means to noninvasively predict the effectiveness of particular chemotherapy drugs in patients with advanced lung cancer.

The investigators are studying lung tumors for ways to image the activity of a protein that pumps certain anticancer drugs out of tumor cells, rendering the drugs ineffective for those individuals.

Positron emission tomography (PET) is one example of molecular imaging technology already in use clinically. PET scans are used, for instance, to detect the spread of certain cancers.

Patients are given a form of sugar (glucose) that contains a weak radioactive label. The labeled sugar is taken up more rapidly by tumor cells than by normal cells because the tumor cells are growing at a faster rate. PET-scan imaging reveals this higher level of uptake, thereby providing a nonsurgical means of detecting an otherwise hidden tumor.

University researchers at the Molecular Imaging Center are developing new applications for existing technologies, such as PET, and exploring new methods of molecular imaging using near-infrared fluorescence and bioluminescence probes.


Current Issue  |  News & Information  |  WUSTL Home

Front Page | More Stories | Medical News | Calendar | Notables | Campus Watch
Washington People | Sports | Record Staff | Employment | WU Magazine | Outlook Magazine

The Record is the University's weekly newspaper for faculty, staff and students.

Questions or comments? Contact the Record at record_editor@aismail.wustl.edu or (314) 935-6603
Technical problems with this Web site? Please contact record_bugs@aismail.wustl.edu
Copyright ©2002 Washington University in St. Louis.  All Rights Reserved.